Encaleret in Autosomal Dominant Hypocalcemia Type 1

Name: Encaleret in Autosomal Dominant Hypocalcemia Type 1: Clinical Implications From the Phase 3 CALIBRATE Trial
Uploaded: 2026-06-17T04:00:00+00:00
Duration: 5 min 48 s
Description: Why is the phase 3 CALIBRATE trial generating so much interest in the autosomal dominant hypocalcemia type 1 (ADH1) community? In this video brief from END

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
Why is the phase 3 CALIBRATE trial generating so much interest in the autosomal dominant hypocalcemia type 1 (ADH1) community? In this video brief from ENDO 2026, Dr. Michael Levine explores the clinical implications surrounding encaleret and discusses how emerging data may influence future approaches to diagnosis, monitoring, and long-term management. Discover what endocrinologists should be watching as the ADH1 treatment landscape continues to evolve.
Provider(s)/Educational Partner(s)

Global Learning Collaborative (GLC) designs and executes continuing education rooted in evidence-based medicine, clinical need, knowledge gap analysis, and careful consideration of learner feedback. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology is founded on a commitment to continuing medical education and the innovative assessment of its effects on clinical practice. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from BridgeBio Pharma, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.

Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.

Michael A. Levine, MD

Recommended

Details

Presenters

Overview
Why is the phase 3 CALIBRATE trial generating so much interest in the autosomal dominant hypocalcemia type 1 (ADH1) community? In this video brief from ENDO 2026, Dr. Michael Levine explores the clinical implications surrounding encaleret and discusses how emerging data may influence future approaches to diagnosis, monitoring, and long-term management. Discover what endocrinologists should be watching as the ADH1 treatment landscape continues to evolve.
Provider(s)/Educational Partner(s)

Global Learning Collaborative (GLC) designs and executes continuing education rooted in evidence-based medicine, clinical need, knowledge gap analysis, and careful consideration of learner feedback. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology is founded on a commitment to continuing medical education and the innovative assessment of its effects on clinical practice. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from BridgeBio Pharma, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.

Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.

Michael A. Levine, MD

CME Learning Centers

CME/CE Topic Areas

Spotlight On:

Lifestyle

Trending Topics

Encaleret in Autosomal Dominant Hypocalcemia Type 1: Clinical Implications From the Phase 3 CALIBRATE Trial

Provider(s)/Educational Partner(s)

Commercial Support

Disclaimer

Provider(s)/Educational Partner(s)

Commercial Support

Disclaimer

Program Chapters

Segment Chapters

Playlist:

Recommended

Transcript